Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder ...

Muscle-invasive bladder cancer remains a significant clinical challenge, due in part to the highly aggressive nature of the ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® ...

A new treatment combination - Keytruda plus Padcev - is now approved for use before and after bladder‑removal surgery, ...

Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the combination of pembrolizumab and enfortumab vedotin for use both before ...

Researchers at MD Anderson Cancer Center have used spatial transcriptomics to chart the internal architecture of ...

Patients saw improved event-free survival and overall survival with presurgical Imfinzi and chemotherapy followed by surgery and postsurgical Imfinzi. Treatment with Imfinzi (durvalumab) before and ...

Bladder cancer patients who have an early but aggressive form of the disease that’s unresponsive to the standard of care now have a new treatment option, an implanted Johnson & Johnson drug/device ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

Memory B cells and tertiary lymphoid structures predicted BCG response and longer recurrence free survival in non muscle ...